IN2012DN02589A - - Google Patents
Download PDFInfo
- Publication number
- IN2012DN02589A IN2012DN02589A IN2589DEN2012A IN2012DN02589A IN 2012DN02589 A IN2012DN02589 A IN 2012DN02589A IN 2589DEN2012 A IN2589DEN2012 A IN 2589DEN2012A IN 2012DN02589 A IN2012DN02589 A IN 2012DN02589A
- Authority
- IN
- India
- Prior art keywords
- binding
- hla
- peptide
- mhc
- binding peptide
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/02—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length in solution
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/12—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by hydrolysis, i.e. solvolysis in general
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/16—Extraction; Separation; Purification by chromatography
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/50—Fusion polypeptide containing protease site
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Virology (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Genetics & Genomics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Pulmonology (AREA)
- Gastroenterology & Hepatology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Transplantation (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US23714709P | 2009-08-26 | 2009-08-26 | |
US33561110P | 2010-01-06 | 2010-01-06 | |
PCT/US2010/002330 WO2011031298A1 (en) | 2009-08-26 | 2010-08-24 | Compositions that induce t cell help |
Publications (1)
Publication Number | Publication Date |
---|---|
IN2012DN02589A true IN2012DN02589A (es) | 2015-08-28 |
Family
ID=43732728
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IN2589DEN2012 IN2012DN02589A (es) | 2009-08-26 | 2010-08-24 |
Country Status (15)
Country | Link |
---|---|
US (1) | US20110110965A1 (es) |
EP (2) | EP3311833A3 (es) |
JP (2) | JP5933437B2 (es) |
KR (2) | KR20120059572A (es) |
CN (3) | CN102574891A (es) |
AU (2) | AU2010293059B2 (es) |
BR (1) | BR112012003977A2 (es) |
CA (1) | CA2771863A1 (es) |
EA (2) | EA023897B1 (es) |
ES (1) | ES2641892T3 (es) |
IL (2) | IL218254A (es) |
IN (1) | IN2012DN02589A (es) |
MX (1) | MX343908B (es) |
PL (1) | PL2470554T3 (es) |
WO (1) | WO2011031298A1 (es) |
Families Citing this family (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MX350667B (es) | 2009-05-27 | 2017-09-12 | Selecta Biosciences Inc | Nanoportadores que poseen componentes con diferentes tasas de liberacion. |
EP3311833A3 (en) * | 2009-08-26 | 2018-07-25 | Selecta Biosciences, Inc. | Compositions that induce t cell help |
EP3388081A1 (en) | 2010-05-26 | 2018-10-17 | Selecta Biosciences, Inc. | Multivalent synthetic nanocarrier vaccines |
US9994443B2 (en) | 2010-11-05 | 2018-06-12 | Selecta Biosciences, Inc. | Modified nicotinic compounds and related methods |
CA2817746A1 (en) * | 2010-11-16 | 2012-05-24 | Selecta Biosciences, Inc. | Immunostimulatory oligonucleotid |
EP2704693A4 (en) | 2011-04-29 | 2015-01-28 | Selecta Biosciences Inc | TAXED RELEASE OF IMMUNOSUPPRESSIVA FROM SYNTHETIC NANOTORIES |
KR20120132183A (ko) * | 2011-05-27 | 2012-12-05 | 포항공과대학교 산학협력단 | 종양 조직에서 유래한 나노소포체 및 이를 이용한 암 백신 |
KR20140050698A (ko) | 2011-07-29 | 2014-04-29 | 셀렉타 바이오사이언시즈, 인크. | 체액성 및 세포독성 t 림프구(ctl) 면역 반응을 발생시키는 합성 나노운반체 |
CN104114572A (zh) | 2011-12-16 | 2014-10-22 | 现代治疗公司 | 经修饰的核苷、核苷酸和核酸组合物 |
US10258698B2 (en) | 2013-03-14 | 2019-04-16 | Modernatx, Inc. | Formulation and delivery of modified nucleoside, nucleotide, and nucleic acid compositions |
CN110251675A (zh) | 2013-05-03 | 2019-09-20 | 西莱克塔生物科技公司 | 降低或预防响应于非变应原性抗原的过敏反应的致耐受性合成纳米载体 |
EP4023249A1 (en) | 2014-04-23 | 2022-07-06 | ModernaTX, Inc. | Nucleic acid vaccines |
EP4159741A1 (en) | 2014-07-16 | 2023-04-05 | ModernaTX, Inc. | Method for producing a chimeric polynucleotide encoding a polypeptide having a triazole-containing internucleotide linkage |
WO2016037163A1 (en) | 2014-09-07 | 2016-03-10 | Selecta Biosciences, Inc. | Methods and compositions for attenuating gene therapy anti-viral transfer vector immune responses |
US10441649B2 (en) * | 2015-02-02 | 2019-10-15 | The University Of Birmingham | Targeting moiety peptide epitope complexes having a plurality of T-cell epitopes |
WO2018169811A1 (en) | 2017-03-11 | 2018-09-20 | Selecta Biosciences, Inc. | Methods and compositions related to combined treatment with anti-inflammatories and synthetic nanocarriers comprising an immunosuppressant |
CN110799529A (zh) | 2017-04-22 | 2020-02-14 | 免疫治疗有限公司 | 改良lamp构建物 |
US20200087365A1 (en) * | 2017-05-02 | 2020-03-19 | Immunomic Therapeutics, Inc | Improved lamp constructs comprising cancer antigens |
BR112020004149A2 (pt) * | 2017-08-31 | 2020-09-08 | Syngulon Sa | métodos e composições para fabricar bacteriocinas e peptídeos antimicrobianos |
WO2019061297A1 (zh) * | 2017-09-29 | 2019-04-04 | 苏州工业园区唯可达生物科技有限公司 | 一种cd4辅助性t细胞表位融合肽及其疫苗 |
TW202003031A (zh) | 2018-04-10 | 2020-01-16 | 瑞士商Ac免疫有限公司 | 抗Aβ治療性疫苗 |
Family Cites Families (125)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4946929A (en) | 1983-03-22 | 1990-08-07 | Massachusetts Institute Of Technology | Bioerodible articles useful as implants and prostheses having predictable degradation rates |
US6309669B1 (en) * | 1984-03-16 | 2001-10-30 | The United States Of America As Represented By The Secretary Of The Army | Therapeutic treatment and prevention of infections with a bioactive materials encapsulated within a biodegradable-biocompatible polymeric matrix |
US4638045A (en) | 1985-02-19 | 1987-01-20 | Massachusetts Institute Of Technology | Non-peptide polyamino acid bioerodible polymers |
US4806621A (en) | 1986-01-21 | 1989-02-21 | Massachusetts Institute Of Technology | Biocompatible, bioerodible, hydrophobic, implantable polyimino carbonate article |
CA1340581C (en) | 1986-11-20 | 1999-06-08 | Joseph P. Vacanti | Chimeric neomorphogenesis of organs by controlled cellular implantation using artificial matrices |
US5736372A (en) | 1986-11-20 | 1998-04-07 | Massachusetts Institute Of Technology | Biodegradable synthetic polymeric fibrous matrix containing chondrocyte for in vivo production of a cartilaginous structure |
US5804178A (en) | 1986-11-20 | 1998-09-08 | Massachusetts Institute Of Technology | Implantation of cell-matrix structure adjacent mesentery, omentum or peritoneum tissue |
US5912017A (en) * | 1987-05-01 | 1999-06-15 | Massachusetts Institute Of Technology | Multiwall polymeric microspheres |
US5019379A (en) | 1987-07-31 | 1991-05-28 | Massachusetts Institute Of Technology | Unsaturated polyanhydrides |
US6130082A (en) | 1988-05-05 | 2000-10-10 | American Cyanamid Company | Recombinant flagellin vaccines |
US5180806A (en) * | 1988-05-16 | 1993-01-19 | The Scripps Research Institute | Polypeptides and compositions of human papillomavirus latent proteins, diagnostic systems and methods |
US5010167A (en) | 1989-03-31 | 1991-04-23 | Massachusetts Institute Of Technology | Poly(amide-and imide-co-anhydride) for biological application |
US5389640A (en) | 1991-03-01 | 1995-02-14 | Minnesota Mining And Manufacturing Company | 1-substituted, 2-substituted 1H-imidazo[4,5-c]quinolin-4-amines |
GB9113809D0 (en) * | 1991-06-26 | 1991-08-14 | Cancer Res Campaign Tech | Papillomavirus l2 protein |
SK279188B6 (sk) * | 1992-06-25 | 1998-07-08 | Smithkline Beecham Biologicals S.A. | Vakcínová kompozícia spôsob jej prípravy a použiti |
US6337070B1 (en) * | 1993-04-29 | 2002-01-08 | Takara Shuzo Co., Ltd. | Polypeptides for use in generating anti-human influenza virus antibodies |
US5399665A (en) | 1992-11-05 | 1995-03-21 | Massachusetts Institute Of Technology | Biodegradable polymers for cell transplantation |
US5928647A (en) * | 1993-01-11 | 1999-07-27 | Dana-Farber Cancer Institute | Inducing cytotoxic T lymphocyte responses |
US5512600A (en) | 1993-01-15 | 1996-04-30 | Massachusetts Institute Of Technology | Preparation of bonded fiber structures for cell implantation |
US5514378A (en) | 1993-02-01 | 1996-05-07 | Massachusetts Institute Of Technology | Biocompatible polymer membranes and methods of preparation of three dimensional membrane structures |
US5543158A (en) * | 1993-07-23 | 1996-08-06 | Massachusetts Institute Of Technology | Biodegradable injectable nanoparticles |
US5565215A (en) * | 1993-07-23 | 1996-10-15 | Massachusettes Institute Of Technology | Biodegradable injectable particles for imaging |
WO1995003035A1 (en) * | 1993-07-23 | 1995-02-02 | Massachusetts Institute Of Technology | Polymerized liposomes with enhanced stability for oral delivery |
US6485729B1 (en) * | 1993-09-13 | 2002-11-26 | Protein Sciences Corporation | Neuraminidase-supplemented compositions |
AUPM358894A0 (en) * | 1994-01-31 | 1994-02-24 | Csl Limited | Modified papilloma virus l2 protein and vlps formed therefrom |
US5693325A (en) * | 1994-03-15 | 1997-12-02 | Molecumetics, Ltd. | Peptide vaccines and methods relating thereto |
US6207646B1 (en) | 1994-07-15 | 2001-03-27 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
US6007845A (en) | 1994-07-22 | 1999-12-28 | Massachusetts Institute Of Technology | Nanoparticles and microparticles of non-linear hydrophilic-hydrophobic multiblock copolymers |
GB9420146D0 (en) * | 1994-10-06 | 1994-11-23 | Cancer Res Campaign Tech | Papillomavirus vaccine |
US5716404A (en) | 1994-12-16 | 1998-02-10 | Massachusetts Institute Of Technology | Breast tissue engineering |
US6123727A (en) | 1995-05-01 | 2000-09-26 | Massachusetts Institute Of Technology | Tissue engineered tendons and ligaments |
US5866132A (en) * | 1995-06-07 | 1999-02-02 | Alberta Research Council | Immunogenic oligosaccharide compositions |
US6095148A (en) | 1995-11-03 | 2000-08-01 | Children's Medical Center Corporation | Neuronal stimulation using electrically conducting polymers |
US5902599A (en) | 1996-02-20 | 1999-05-11 | Massachusetts Institute Of Technology | Biodegradable polymer networks for use in orthopedic and dental applications |
US6946133B1 (en) * | 1996-03-20 | 2005-09-20 | The United States Of America As Represented By The Department Of Health And Human Services | Prostate specific antigen oligo-epitope peptide |
JP2000515741A (ja) * | 1996-07-17 | 2000-11-28 | アメリカ合衆国 | 感染性パピローマウイルス偽ウイルス粒子 |
CA2262001C (en) * | 1996-08-05 | 2003-05-20 | President And Fellows Of Harvard College | Mhc binding peptide oligomers and methods of use |
US6368598B1 (en) * | 1996-09-16 | 2002-04-09 | Jcrt Radiation Oncology Support Services, Inc. | Drug complex for treatment of metastatic prostate cancer |
DE69737935T2 (de) | 1996-10-25 | 2008-04-03 | Minnesota Mining And Manufacturing Co., St. Paul | Die Immunantwort modifizierende Verbindung zur Behandlung von durch TH2 vermittelten und verwandten Krankheiten |
US6211159B1 (en) | 1997-04-11 | 2001-04-03 | University Of Toronto | Flagellin gene, FlaC of campylobacter |
US6060082A (en) * | 1997-04-18 | 2000-05-09 | Massachusetts Institute Of Technology | Polymerized liposomes targeted to M cells and useful for oral or mucosal drug delivery |
US5837752A (en) | 1997-07-17 | 1998-11-17 | Massachusetts Institute Of Technology | Semi-interpenetrating polymer networks |
ATE423789T1 (de) * | 1997-09-16 | 2009-03-15 | Univ Oregon Health & Science | Rekombinante mhc-moleküle welche nützlich sind für die manipulation von antigen-spezifischen t- zellen |
NZ504800A (en) | 1997-11-28 | 2001-10-26 | Sumitomo Pharma | 6-Amino-9-benzyl-8-hydroxy-purine derivatives and interferon inducers, antiviral agents, anticancer agents and therapeutic agents for immunologic diseases thereof |
US6254890B1 (en) * | 1997-12-12 | 2001-07-03 | Massachusetts Institute Of Technology | Sub-100nm biodegradable polymer spheres capable of transporting and releasing nucleic acids |
US6197229B1 (en) * | 1997-12-12 | 2001-03-06 | Massachusetts Institute Of Technology | Method for high supercoiled DNA content microspheres |
US6632922B1 (en) | 1998-03-19 | 2003-10-14 | The Regents Of The University Of California | Methods and compositions for controlled polypeptide synthesis |
US6506577B1 (en) | 1998-03-19 | 2003-01-14 | The Regents Of The University Of California | Synthesis and crosslinking of catechol containing copolypeptides |
US6686446B2 (en) | 1998-03-19 | 2004-02-03 | The Regents Of The University Of California | Methods and compositions for controlled polypeptide synthesis |
GB9808932D0 (en) * | 1998-04-27 | 1998-06-24 | Chiron Spa | Polyepitope carrier protein |
ATE518956T1 (de) * | 1998-05-13 | 2011-08-15 | Epimmune Inc | Expressionsvektoren zur stimulierung einer immunantwort und verfahren zu deren verwendung |
EP1388586A3 (en) * | 1998-05-29 | 2004-05-26 | Epimmune Inc. | Identification of broadly reactive DR restricted epitopes |
CA2332786A1 (en) * | 1998-05-29 | 1999-12-02 | Epimmune Inc. | Identification of broadly reactive dr restricted epitopes |
US6306640B1 (en) * | 1998-10-05 | 2001-10-23 | Genzyme Corporation | Melanoma antigenic peptides |
EE200100203A (et) * | 1998-10-05 | 2002-10-15 | M & E Biotech A/S | Meetod immuunvastuse indutseerimiseks polüpeptiidse antigeeni vastu ja rakuga seotud polüpeptiidse antigeeni mahasurumiseks loomorganismil, selle meetodi kasutamine eesnäärme- ja rinnavähi raviks ning immunogeenne kompositsioon |
ES2284287T3 (es) * | 1998-10-16 | 2007-11-01 | Glaxosmithkline Biologicals S.A. | Sistemas adyuvantes y vacunas. |
US6232082B1 (en) * | 1998-12-01 | 2001-05-15 | Nabi | Hapten-carrier conjugates for treating and preventing nicotine addiction |
HU229255B1 (en) * | 1999-04-19 | 2013-10-28 | Smithkline Beecham Biolog | Vaccines |
KR100669053B1 (ko) * | 1999-04-23 | 2007-01-15 | 알자 코포레이션 | 리포좀에 사용하기 위한 절단가능 결합을 갖는 콘쥬게이트 |
US7238368B2 (en) * | 1999-04-23 | 2007-07-03 | Alza Corporation | Releasable linkage and compositions containing same |
US6800296B1 (en) * | 1999-05-19 | 2004-10-05 | Massachusetts Institute Of Technology | Modification of surfaces using biological recognition events |
US7223398B1 (en) | 1999-11-15 | 2007-05-29 | Dynavax Technologies Corporation | Immunomodulatory compositions containing an immunostimulatory sequence linked to antigen and methods of use thereof |
WO2001064164A2 (en) | 2000-02-28 | 2001-09-07 | Genesegues, Inc. | Nanocapsule encapsulation system and method |
US20030129251A1 (en) | 2000-03-10 | 2003-07-10 | Gary Van Nest | Biodegradable immunomodulatory formulations and methods for use thereof |
US20020165176A1 (en) * | 2000-05-01 | 2002-11-07 | Haynes Joel R. | Nucleic acid immunization |
AU2001252458A1 (en) * | 2000-05-05 | 2001-11-20 | Martin Bachmann | Molecular antigen arrays and vaccines |
US7192725B2 (en) | 2000-05-19 | 2007-03-20 | University Of Toronto | Flagellin gene, flaC of Campylobacter |
GB0025414D0 (en) | 2000-10-16 | 2000-11-29 | Consejo Superior Investigacion | Nanoparticles |
US7097837B2 (en) * | 2001-02-19 | 2006-08-29 | Pharmexa A/S | Synthetic vaccine agents |
US20030175950A1 (en) * | 2001-05-29 | 2003-09-18 | Mcswiggen James A. | RNA interference mediated inhibition of HIV gene expression using short interfering RNA |
US6818732B2 (en) | 2001-08-30 | 2004-11-16 | The Regents Of The University Of California | Transition metal initiators for controlled poly (beta-peptide) synthesis from beta-lactam monomers |
AU2003230806B2 (en) | 2002-04-04 | 2009-05-07 | Zoetis Belgium S.A. | Immunostimulatory G,U-containing oligoribonucleotides |
FR2840499B1 (fr) * | 2002-05-30 | 2004-12-10 | Cit Alcatel | Procede et dispositif de controle d'acces a un reseau local de communications sans fil |
US20060189554A1 (en) * | 2002-09-24 | 2006-08-24 | Russell Mumper | Nanoparticle-Based vaccine delivery system containing adjuvant |
PL376792A1 (pl) * | 2002-10-23 | 2006-01-09 | Glaxosmithkline Biologicals S.A. | Sposoby szczepienia przeciwko malarii |
AU2004204942A1 (en) * | 2003-01-08 | 2004-07-29 | Xencor, Inc | Novel proteins with altered immunogenicity |
JP4509999B2 (ja) * | 2003-02-17 | 2010-07-21 | ブルクハルト,ペーター | 医薬送達及び抗原提示システムとしてのペプチドナノ粒子 |
US7727969B2 (en) * | 2003-06-06 | 2010-06-01 | Massachusetts Institute Of Technology | Controlled release nanoparticle having bound oligonucleotide for targeted delivery |
CA2534060C (en) * | 2003-07-30 | 2012-06-12 | Vaccine Research Institute Of San Diego | Hepatitis virus core proteins as vaccine platforms and methods of use thereof |
US20050137156A1 (en) * | 2003-08-09 | 2005-06-23 | Johnston Stephen A. | Methods and compositions for generating an immune response |
US20080160089A1 (en) * | 2003-10-14 | 2008-07-03 | Medivas, Llc | Vaccine delivery compositions and methods of use |
DE10347710B4 (de) * | 2003-10-14 | 2006-03-30 | Johannes-Gutenberg-Universität Mainz | Rekombinante Impfstoffe und deren Verwendung |
WO2005051351A2 (en) * | 2003-11-21 | 2005-06-09 | Alza Corporation | Gene delivery mediated by liposome-dna complex with cleavable peg surface modification |
WO2005101466A2 (en) | 2003-12-19 | 2005-10-27 | The University Of North Carolina At Chapel Hill | Methods for fabricating isolated micro- and nano- structures using soft or imprint lithography |
TW200533750A (en) | 2004-02-19 | 2005-10-16 | Coley Pharm Group Inc | Immunostimulatory viral RNA oligonucleotides |
CA2566506A1 (en) * | 2004-06-01 | 2005-12-15 | Innogenetics N.V. | Peptides for inducing a ctl and/or htl response to hepatitis c virus |
JP2008512350A (ja) | 2004-07-01 | 2008-04-24 | イェール ユニバーシティ | 標的化され、そして高密度で薬物が負荷されるポリマー性物質 |
WO2006014579A2 (en) * | 2004-07-08 | 2006-02-09 | The Regents Of California | Enhancing class i antigen presentation with synthetic sequences |
US8017151B2 (en) * | 2004-09-07 | 2011-09-13 | Board Of Regents Of The University Of Nebraska By And Behalf Of The University Of Nebraska Medical Center | Amphiphilic polymer-protein conjugates and methods of use thereof |
AU2005291058B2 (en) * | 2004-10-01 | 2011-09-29 | Midatech Limited | Nanoparticles comprising antigens and adjuvants and immunogenic structure |
WO2006042333A2 (en) * | 2004-10-12 | 2006-04-20 | Xencor, Inc. | Prediction and assessment of immunogenicity |
MY159370A (en) | 2004-10-20 | 2016-12-30 | Coley Pharm Group Inc | Semi-soft-class immunostimulatory oligonucleotides |
WO2007001448A2 (en) * | 2004-11-04 | 2007-01-04 | Massachusetts Institute Of Technology | Coated controlled release polymer particles as efficient oral delivery vehicles for biopharmaceuticals |
US20090162400A1 (en) * | 2004-12-21 | 2009-06-25 | Powell Thomas J | Compositions of influenza viral proteins and methods of use thereof |
CA2596698C (en) * | 2005-02-01 | 2017-05-16 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Papillomavirus l2 n-terminal peptides for the induction of broadly cross-neutralizing antibodies |
AU2006241149A1 (en) | 2005-04-26 | 2006-11-02 | Coley Pharmaceutical Gmbh | Modified oligoribonucleotide analogs with enhanced immunostimulatory activity |
WO2007022151A2 (en) * | 2005-08-15 | 2007-02-22 | Vaxin, Inc. | Immunization of avians by administration of non-replicating vectored vaccines |
CA2630738C (en) | 2005-11-25 | 2013-09-03 | Coley Pharmaceutical Gmbh | Immunostimulatory oligoribonucleotides |
CA2637678A1 (en) * | 2006-01-26 | 2007-08-09 | University Of Massachusetts | Rna silencing agents for use in therapy and nanotransporters for efficient delivery of same |
EP2019691B1 (en) * | 2006-05-15 | 2020-08-12 | Massachusetts Institute of Technology | Polymers for functional particles |
WO2007137117A2 (en) * | 2006-05-17 | 2007-11-29 | Massachusetts Institute Of Technology | Aptamer-directed drug delivery |
WO2008033432A2 (en) | 2006-09-12 | 2008-03-20 | Coley Pharmaceutical Group, Inc. | Immune modulation by chemically modified ribonucleosides and oligoribonucleotides |
US20100111973A1 (en) * | 2006-09-22 | 2010-05-06 | Glenn Dranoff | Methods for treating mica-related disorders |
JP5650406B2 (ja) * | 2007-03-07 | 2015-01-07 | ユーティーアイ リミテッド パートナーシップ | 自己免疫状態の予防および治療のための組成物および方法 |
US20090074828A1 (en) * | 2007-04-04 | 2009-03-19 | Massachusetts Institute Of Technology | Poly(amino acid) targeting moieties |
EP2468763B1 (en) * | 2007-05-31 | 2014-06-18 | Academisch Ziekenhuis Leiden h.o.d.n. LUMC | HPV epitopes targeted by T cells infiltrating cervical malignancies for use in vaccines |
CA2697049A1 (en) * | 2007-08-21 | 2009-02-26 | Dynavax Technologies Corporation | Composition and methods of making and using influenza proteins |
JP2011500569A (ja) * | 2007-10-12 | 2011-01-06 | マサチューセッツ インスティテュート オブ テクノロジー | ワクチンナノテクノロジー |
WO2009109428A2 (en) * | 2008-02-01 | 2009-09-11 | Alpha-O Peptides Ag | Self-assembling peptide nanoparticles useful as vaccines |
AU2009214042B2 (en) * | 2008-02-14 | 2014-02-13 | Katholieke Universiteit Leuven | Immunotherapy targeting intracellular pathogens |
CA2716622A1 (en) * | 2008-02-26 | 2009-09-03 | The Regents Of The University Of California | Glycopeptides and methods of making and using them |
EP2421561A2 (en) * | 2009-04-21 | 2012-02-29 | Selecta Biosciences, Inc. | Immunonanotherapeutics providing a th1-biased response |
MX350667B (es) * | 2009-05-27 | 2017-09-12 | Selecta Biosciences Inc | Nanoportadores que poseen componentes con diferentes tasas de liberacion. |
EP3311833A3 (en) * | 2009-08-26 | 2018-07-25 | Selecta Biosciences, Inc. | Compositions that induce t cell help |
WO2011085231A2 (en) * | 2010-01-08 | 2011-07-14 | Selecta Biosciences, Inc. | Synthetic virus-like particles conjugated to human papillomavirus capsid peptides for use as vaccines |
US20110262491A1 (en) * | 2010-04-12 | 2011-10-27 | Selecta Biosciences, Inc. | Emulsions and methods of making nanocarriers |
EP3388081A1 (en) * | 2010-05-26 | 2018-10-17 | Selecta Biosciences, Inc. | Multivalent synthetic nanocarrier vaccines |
AU2011291522A1 (en) * | 2010-08-20 | 2013-01-24 | Selecta Biosciences, Inc. | Synthetic nanocarrier vaccines comprising peptides obtained or derived from human influenza A virus M2E |
CA2809029A1 (en) * | 2010-08-23 | 2012-03-01 | Selecta Biosciences, Inc. | Targeted multi-epitope dosage forms for induction of an immune response to antigens |
US9994443B2 (en) * | 2010-11-05 | 2018-06-12 | Selecta Biosciences, Inc. | Modified nicotinic compounds and related methods |
US20120171229A1 (en) * | 2010-12-30 | 2012-07-05 | Selecta Biosciences, Inc. | Synthetic nanocarriers with reactive groups that release biologically active agents |
WO2012135010A2 (en) * | 2011-03-25 | 2012-10-04 | Selecta Biosciences, Inc. | Osmotic mediated release synthetic nanocarriers |
EP2704693A4 (en) * | 2011-04-29 | 2015-01-28 | Selecta Biosciences Inc | TAXED RELEASE OF IMMUNOSUPPRESSIVA FROM SYNTHETIC NANOTORIES |
KR20140050698A (ko) * | 2011-07-29 | 2014-04-29 | 셀렉타 바이오사이언시즈, 인크. | 체액성 및 세포독성 t 림프구(ctl) 면역 반응을 발생시키는 합성 나노운반체 |
WO2013036303A2 (en) * | 2011-09-06 | 2013-03-14 | Selecta Biosciences, Inc. | Induced tolerogenic dendritic cells to reduce systemic inflammatory cytokines |
-
2010
- 2010-08-24 EP EP17171181.5A patent/EP3311833A3/en not_active Withdrawn
- 2010-08-24 EA EA201270313A patent/EA023897B1/ru not_active IP Right Cessation
- 2010-08-24 IN IN2589DEN2012 patent/IN2012DN02589A/en unknown
- 2010-08-24 KR KR1020127007388A patent/KR20120059572A/ko active Application Filing
- 2010-08-24 EA EA201592264A patent/EA201592264A1/ru unknown
- 2010-08-24 MX MX2012002357A patent/MX343908B/es active IP Right Grant
- 2010-08-24 BR BR112012003977A patent/BR112012003977A2/pt not_active Application Discontinuation
- 2010-08-24 CN CN2010800428527A patent/CN102574891A/zh active Pending
- 2010-08-24 JP JP2012526724A patent/JP5933437B2/ja not_active Expired - Fee Related
- 2010-08-24 KR KR1020177017217A patent/KR101873179B1/ko active IP Right Grant
- 2010-08-24 CN CN201710829622.9A patent/CN107617110A/zh active Pending
- 2010-08-24 ES ES10815729.8T patent/ES2641892T3/es active Active
- 2010-08-24 AU AU2010293059A patent/AU2010293059B2/en not_active Ceased
- 2010-08-24 CN CN201710829621.4A patent/CN107715118A/zh active Pending
- 2010-08-24 US US12/862,076 patent/US20110110965A1/en not_active Abandoned
- 2010-08-24 WO PCT/US2010/002330 patent/WO2011031298A1/en active Application Filing
- 2010-08-24 EP EP10815729.8A patent/EP2470554B1/en active Active
- 2010-08-24 CA CA2771863A patent/CA2771863A1/en not_active Abandoned
- 2010-08-24 PL PL10815729T patent/PL2470554T3/pl unknown
-
2012
- 2012-02-22 IL IL218254A patent/IL218254A/en active IP Right Grant
-
2015
- 2015-12-25 JP JP2015252769A patent/JP2016121149A/ja not_active Ceased
-
2017
- 2017-03-02 AU AU2017201438A patent/AU2017201438A1/en not_active Abandoned
- 2017-10-15 IL IL255009A patent/IL255009A0/en unknown
Also Published As
Publication number | Publication date |
---|---|
IL218254A (en) | 2017-11-30 |
US20110110965A1 (en) | 2011-05-12 |
CN107715118A (zh) | 2018-02-23 |
JP5933437B2 (ja) | 2016-06-08 |
IL218254A0 (en) | 2012-04-30 |
BR112012003977A2 (pt) | 2017-06-06 |
AU2010293059B2 (en) | 2017-03-16 |
EA201270313A1 (ru) | 2012-09-28 |
AU2010293059A1 (en) | 2012-03-08 |
MX2012002357A (es) | 2012-04-10 |
IL255009A0 (en) | 2017-12-31 |
WO2011031298A1 (en) | 2011-03-17 |
EP2470554A4 (en) | 2014-05-07 |
CN107617110A (zh) | 2018-01-23 |
PL2470554T3 (pl) | 2018-02-28 |
MX343908B (es) | 2016-11-28 |
AU2017201438A1 (en) | 2017-03-16 |
EP3311833A3 (en) | 2018-07-25 |
ES2641892T3 (es) | 2017-11-14 |
KR101873179B1 (ko) | 2018-06-29 |
EA201592264A1 (ru) | 2016-08-31 |
KR20120059572A (ko) | 2012-06-08 |
EP2470554B1 (en) | 2017-06-28 |
CA2771863A1 (en) | 2011-03-17 |
EP2470554A1 (en) | 2012-07-04 |
EA023897B1 (ru) | 2016-07-29 |
JP2016121149A (ja) | 2016-07-07 |
EP3311833A2 (en) | 2018-04-25 |
CN102574891A (zh) | 2012-07-11 |
JP2013503159A (ja) | 2013-01-31 |
KR20170076804A (ko) | 2017-07-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IN2012DN02589A (es) | ||
PH12018501517A1 (en) | Neisseria meningitidis compositions and methods thereof | |
MX2010001779A (es) | Peptidos para vacunas. | |
EA201792245A1 (ru) | Биоконъюгаты и их применения | |
EP3533461A3 (en) | Prame derived peptides and immunogenic compositions comprising these | |
WO2009088401A3 (en) | Immunostimulatory combinations of tlr3 ligands with tlr2 and/or tlr9 agonists and methods of use | |
MX2007015935A (es) | Agentes y metodos basados en el uso del dominio eda de la fibronectina. | |
GB0710529D0 (en) | Vaccine | |
EP2166845A4 (en) | ALPHA CONNEXIN C TERMINAL (ACT) PEPTIDES FOR THE TREATMENT OF AGE-RELATED MACULAR AGENCY | |
MX2010010457A (es) | Vectores recombinantes de rinovirus. | |
EP2402364A3 (en) | A nonapeptide with anti-tumour activity | |
HK1142803A1 (en) | Compositions comprising myelin basic protein peptides and medical uses thereof | |
MX2011008179A (es) | Peptidos para vacuna. | |
EP2552462A4 (en) | CCN3 PEPTIDES AND ANALOGS THEREOF FOR THERAPEUTIC USE | |
WO2011053789A3 (en) | Pharmaceutical composition and methods to enhance cytotoxic t-cell recognition and maintain t-cell memory against a pathogenic disease | |
PH12015501033A1 (en) | Peptides | |
WO2014039074A3 (en) | Therapeutic compositions and related methods | |
MX2011012270A (es) | Peptidos de factor vii tolerogenico. | |
EP2569327A4 (en) | EIF4E BINDING PEPTIDES | |
WO2009095646A3 (en) | Peptides from factor viii | |
GB0818080D0 (en) | Immunogenic peptides | |
EA200870188A1 (ru) | Связывающие fgf2 пептиды и их применение | |
GB201013343D0 (en) | Compositions and methods for inducing platelet aggregation | |
WO2009147384A3 (en) | Peptides derived from the neural-restrictive silencer factor rest and use thereof | |
MY178220A (en) | Gold binding polypeptide |